Article History
Received: 7 November 2023
Revised: 19 February 2024
Accepted: 7 March 2024
First Online: 13 March 2024
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Medical Ethics Committee II of the Medical Faculty Mannheim of the Heidelberg University which approved the study and confirmed that the study conformed to the regulations formulated in the World Medical Association Declaration of Helsinki.
: The ethics committee waived the necessity of an informed written consent by the patients, since the globes had been enucleated up to 60 years before start of the present investigations, with the enucleation as part of routinely taken clinical care of the patients.
: Jost B. Jonas, S. Panda-Jonas, Rahul A. Jonas: European patent EP 3 271 392, JP 2021–119187, and US 2021 0340237 A1: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Patent application: European patent office number: 23170806.6: Jonas JB, Panda-Jonas S, Jonas RA, Jonas SB. Epidermal Growth Factor Inhibition in the Prophylactic or Therapeutic Treatment of Unwanted Proliferation, Migration or Metaplasia of the Retinal Pigment Epithelium.